Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-23T09:06:41.117Z Has data issue: false hasContentIssue false
  • English
  • Français

Evaluating dose to thyroid gland in women with breast cancer during radiotherapy with different radiation energies at supraclavicular fossa region

Published online by Cambridge University Press:  23 July 2018

Marjaneh Mirsadraei ,
Mehdi Seilanian Toosi ,
Shokoufeh Mohebbi  and
Hojjat Khalili-Hezarjaribi
Marjaneh Mirsadraei
Affiliation:
Research Department, Reza Radiotherapy and Oncology Center, Mashhad, Islamic Republic of Iran
Mehdi Seilanian Toosi
Affiliation:
Research Department, Reza Radiotherapy and Oncology Center, Mashhad, Islamic Republic of Iran
Shokoufeh Mohebbi
Affiliation:
Research Department, Reza Radiotherapy and Oncology Center, Mashhad, Islamic Republic of Iran
Hojjat Khalili-Hezarjaribi*
Affiliation:
Research Department, Reza Radiotherapy and Oncology Center, Mashhad, Islamic Republic of Iran
*
Author for correspondence: Hojjat Khalili-Hezarjaribi, Research Department, Reza Radiotherapy and Oncology Center, Mashhad, Islamic Republic of Iran. Tel: +985135224472; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background and aim

During the treatment of breast cancer, radiotherapy to the supraclavicular fossa region results in absorption of radiation by the thyroid gland and consequently leads to hypothyroidism in 40% of patients. The aim of this study was to compare thyroid gland radiation absorption during radiotherapy with different anterioposterior beam radiation of 6–15 and 15–15 MV photon beam energies.

Materials and methods

In total, 29 patients with breast cancer were recruited to this study. Adjuvant radiotherapy with a total dose of 50 Gy was performed for each participant. Thyroid gland dosimetric measurements were evaluated including, mean dose, minimum and maximum dose, and V20, V30, V40 and V50 (percentage of thyroid volume receiving ≥20, ≥30, ≥40 and ≥50 Gy, respectively). The irradiation delivered doses were measured using Prowess Panther treatment planning system (Version 5.5). All data were evaluated using SPSS software.

Results

In total, 29 subjects with mean age of 53·4±9·4 were studied. According to the obtained results, at 15–15 MV energies, a significantly lower dose was absorbed by the thyroid gland, was observed in contrast to their counterparts who were treated with 6–15 MV photon beam energies.

Findings

Using 15–15 MV photon beam energies field can significantly reduce the absorbed dose to the thyroid gland and consequently can reduce the risk of developing hypothyroidism in breast cancer patients treated with radiotherapy.

Keywords

breast cancerhypothyroidismradiotherapysupraclavicular fossa radiationthyroid gland irradiation
Type
Original Article
Information
Journal of Radiotherapy in Practice , Volume 17 , Issue 4 , December 2018 , pp. 373 - 376
Copyright
© Cambridge University Press 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Ghoncheh, M, Pournamdar, Z, Salehiniya, H. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev 2016; 17: 43–46.Google Scholar
2. Leong, S P, Shen, Z Z, Liu, T J et al. Is breast cancer the same disease in Asian and Western countries? World J Surg 2010; 34: 2308–2324.Google Scholar
3. Hortobagyi, G N, de la Garza Salazar, J, Pritchard, K et al. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 2005; 6: 391–401.Google Scholar
4. American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2016-2017. Atlanta: American Cancer Society, 2016.Google Scholar
5. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of RT after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 2011; 378: 1707–1716.Google Scholar
6. Buchholz, T A. Radiotherapy and survival in breast cancer. Lancet 2011; 378: 1680–1682.Google Scholar
7. Akın, M, Ergen, A, Unal, A, Bese, N. Irradiation doses on thyroid gland during the postoperative irradiation for breast cancer. J Can Res Ther 2014; 10: 942–944.Google Scholar
8. Prabhakar, R, Rath, G K, Julka, P K, Ganesh, T, Joshi, R C, Manoharan, N. Breast dose heterogeneity in CT-based RT treatment planning. J Med Phys 2008; 33: 43–48.Google Scholar
9. Charaghvandia, R K, Yoo, S, Asselen, B V, Rodrigues, A, van den Bongard, D H J G, Horton, J K. Treatment constraints for single dose external beam preoperative partial breast irradiation in early-stage breast cancer. Clin Trans Radiat Oncol 2017; 6: 7–14.Google Scholar
10. Pignol, J P, Olivotto, I, Rakovitch, E et al. A multicenter radomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 2008; 26: 2085–2092.Google Scholar
11. Harsolia, A, Kestin, L, Grills, I et al. Intensity-modulated radiotherapy results in significant decrease in clinical toxicities compared with conventional wedge-based breast RT. Int J Radiat Oncol Biol Phys 2007; 68: 1375–1380.Google Scholar
12. Paszat, L F, Mackillop, W J, Groome, P A, Schulze, K, Holowaty, E. Mortality from myocardial infarction following postlumpectomy RT for breast cancer; a population-based study in Ontario, Canada. Int J Radiat Oncol Biol Phys 2007; 69: 918–924.Google Scholar
13. Correa, C R, Das, I J, Litt, H I et al. Association between tangential beam treatment parameters and cardiac abnormalities after definitive radiation treatment for left-sided breast cancer. Int J Radiat Oncol Biol Phys 2008; 72: 508–516.Google Scholar
14. Akın, M, Ergen, A, Unal, A, Bese, N. Irradiation doses on thyroid gland during the postoperative irradiation for breast cancer. JCRT 2014; 10: 942–944.Google Scholar
15. Sinard, R J, Tobin, E J, Mazzaferri, E L et al. HT after treatment for nonthyroid head and neck cancer. Arch Otolaryngol Head Neck Surg 2000; 126: 652–657.Google Scholar
16. Jereczek-Fossa, B A, Alterio, D, Jassem, J, Gibelli, B, Tradati, N, Orecchia, R. Radiotherapy-induced thyroid disorders. Cancer Treat Rev 2004; 30: 369–384.Google Scholar
17. Tell, R, Lundell, G, Nilsson, B, Sjödin, H, Lewin, F, Lewensohn, R. Long-term incidence of hypothroidism after radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2004; 60: 395–400.Google Scholar
18. Smith, G L, Smith, B D, Giordano, S H et al. Risk of HT in older breast cancer patients treated with radiation. Cancer 2008; 112: 1371–1379.Google Scholar
19. Reinertsen, K V, Cvancarova, M, Wist, E et al. Thyroid function in women after multimodal treatment for breast cancer stage II/III: comparison with controls from a population sample. Int J Radiat Oncol Biol Phys 2009; 75: 764–770.Google Scholar
20. Kikawa, Y, Kosaka, Y, Hashimoto, K et al. Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey. ESMO Open 2017; 2: e000161.Google Scholar
21. Alhosainy, A M, Mohamed, A E, Elattar, A Z. The impact of SC irradiation on thyroid function and size in postoperative breast cancer patients by comparing 2D versus 3D-CRT. Life Sci J 2015; 12: 57–62.Google Scholar
22. Akyurek, S, Babalioglu, I, Kose, K, Gokce, S C. Thyroid dysfunction following SC irradiation in the management of carcinoma of the breast. Int J Hematol Oncol 2014; 24: 139–144.Google Scholar
23. Mercado, G, Adelstein, D J, Saxton, J P, Secic, M, Larto, M A, Lavertu, P. Hypothyroidism: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma. Cancer 2001; 92: 2892–2897.Google Scholar
24. Johansen, S, Reinertsen, K, Knutstad, K, Olsen, D, Fossa, S. Dose distribution in the thyroid gland following radiation therapy of breast cancer-a retrospective study. Radiat Oncol 2011; 6: 68.Google Scholar
25. Wolny-Rokicka, E, Tukiendorf, A, Wydmański, J, Roszkowska, D, Staniul, B, Zembroń-Łacny, A. Thyroid function after postoperative radiation therapy in patients with breast cancer. Asian Pac J Cancer Prev 2016; 17: 4577–4581.Google Scholar
26. Ronjom, M F, Brink, C, Bentzen, S M et al. HT after primary radiotherapy for head and neck squamous cell carcinoma: normal tissue complication probability modeling with latent time correction. Radiother Oncol 2013; 2013 (109): 317–322.Google Scholar
27. Alhosainy, A M., Mohamed, A E, Elattar, A Z. The impact of supraclavicular irradiation on thyroid function and size in postoperative breast cancer patients by comparing 2D versus 3D-CRT. Life Sci J 2015; 12: 57–62.Google Scholar
28. Kuten, A, Lubochitski, R, Fishman, G, Dale, J, Stein, M E. Post radiotherapy HT: radiation dose response and chemotherapeutic radio sensitization at less than 40 Gy. J Surg Oncol 1996; 61: 281–283.Google Scholar